---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039356"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:23:33.786457+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Beam Q2 net loss $82.8M; BEAM-101/201 trials advance, in vivo programs accelerated

## Summary
- Q2 net loss $82.8M ($1.08/shr) vs $72.0M ($1.02/shr) in Q2 2022; R&D spend $97.6M (up 31% YoY).
- Cash $1.1B unchanged from year-end 2022; runway extends at least into 2025.
- BEACON trial: consented patients sufficient to fill sentinel and initiate expansion; initial data expected 2024.
- BEAM-201: first patient consented, dosing expected Q3 2023; multiple clinical sites open.
- BEAM-302 accelerated to first in vivo liver regulatory filing in Q1 2024; BEAM-301 filing in H1 2024.

## SEC filing metadata
- accession: 0000950170-23-039356
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000095017023039356/0000950170-23-039356-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000095017023039356/beam-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039356
- JSON: https://secwatch.observer/filing/0000950170-23-039356.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039356.txt

## Key facts
- Earnings Releases
  Beam Therapeutics Inc. reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: On August 8, 2023, Beam Therapeutics Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1745999/000095017023039356/0000950170-23-039356-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.